Approval · Notice of Compliance 8912 · 2007
ACTONEL: Notice of Compliance 8912
Issued July 17, 2007
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 8912
- Date
- July 17, 2007
- Company
- Procter & Gamble Pharmaceuticals Canada, IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New dosing recommendation and new strength tablet, 75 mg, on two consecutive days per month
- Therapeutic class
- Bone metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACTONEL | 02297787 | Cancelled Post Market |
Medicinal ingredients
- RISEDRONATE SODIUM 75 MG per TAB